Skip to main content
SpringerLink
Log in

Darunavir/ritonavir dominates most other PI/ritonavir combinations

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Brogan A, Soorapanth S, Donatz V, Hill A, Smets E.Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of hiv-1 infection in Germany. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: (plus poster) abstr. PIN48, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Darunavir/ritonavir dominates most other PI/ritonavir combinations. Pharmacoecon. Outcomes News 591, 6 (2009). https://doi.org/10.2165/00151234-200905910-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00008

Keywords

Search

Navigation